Avsar.

Healthcare · Biotechnology

Advanced Enzyme Technologies Ltd (ADVENZYMES)

₹317.35

Mkt cap
₹3,901 Cr
P/E ratio
24.30
P/B
2.17
Div yield
1.49%
ROE
10.50%
ROCE
13.90%
EPS (TTM)
₹13.06
Book value
₹146
52W range
255–392
Sector
Healthcare

Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes. [1]

NSE ADVENZYMESBSE 540025www.advancedenzymes.com
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−19.06% from high
₹317
₹255+24.30% from low₹392
Current
₹317.35
Prev close
₹317.55
Day
−0.06%
Price performance
1D
−0.06%
1W
−0.53%
1M
−8.90%
3M
+6.12%
6M
+17.28%
1Y
−3.08%
YTD
+5.03%

Financials

F
Revenue, profit & margin
P/E ratio
24.3×
ADVENZYMES is 49% below the sector median of 47.4×
ADVENZYMES24.3×
Sector median47.4×
 Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Trend
Sales139147158161158155146169167186185172203
Expenses95103107107102103104114122129124123140
Operating Profit44445154555142554656604963
OPM %32%30%32%33%35%33%29%33%27%30%33%29%31%
Other Income77614-671089910207
Interest1111111111111
Depreciation899999991010101010
Profit before tax42414859404942534355605860
Tax %24%29%27%28%25%28%21%27%38%26%25%26%24%
Net Profit32293542303533392740454345
EPS in Rs2.872.583.083.742.533.052.943.372.373.573.873.803.84
Raw PDF

Earnings

EResults dates & reactions
No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

No reaction history yet.
No quarterly filings ingested yet.

Corporate actions

CLast 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Shareholding

Sas of Mar 2026
43.26%Promoter
Promoters43.26%0.22
FIIs25.50%0.35
DIIs5.41%0.10
Public25.85%0.23
Ownership trend

Peers

P6 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Anthem Bioscienc₹761.7070.4442,8990.26%190+128.88%611+26.44%30.45%
Advanced Enzyme₹348.3524.313,9011.49%45+61.91%203+21.65%13.89%
CCME Global₹125.00—5660.00%−1−2,400.00%0—−2.92%
Vivo Bio Tech₹23.04—510.00%−5−586.79%14+15.54%7.29%
Shree Ganesh Bio₹0.5759.79230.00%0+84.21%2−29.57%0.80%
Genomic Valley₹33.36339.67100.00%0+87.50%0−84.62%1.02%
Median: 3 Co.₹348.3547.383,9010.26%45+61.91%203+24.05%13.89%

Filings

D
Annual reports16
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2011bseDRHP
Concall transcripts97
TranscriptPPTRECTranscriptPPTRECTranscriptPPTPPTTranscriptPPTTranscriptPPTTranscriptPPTTranscriptPPTRECTranscriptPPTTranscriptPPTTranscriptPPT
Credit ratings6
Rating update 30 AprcrisilRating update 13 FebicraRating update 30 Jan 2025crisilRating update 28 Dec 2023crisilRating update 31 Oct 2022crisilRating update 18 Aug 2021crisil
Announcements5
Closure of Trading Window 25 Jun - Trading window closed from July 1, 2026 till 48 hours after Q1 FY27 results.Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Jun - Newspaper Publication - Notice to Equity Shareholders of the Company regarding transfer of shares to the Investor Education and Protection Fund (IEPF) and Unclaimed Dividend …Announcement under Regulation 30 (LODR)-Change in Directorate 11 Jun - Ms. Rajshree Patel ceases as Independent Director effective June 11, 2026.Announcement under Regulation 30 (LODR)-Updates on Acquisition 6 Jun - Company completed ₹2.5 million investment in wholly owned subsidiary ANPL via rights issue.Compliances-Reg.24(A)-Annual Secretarial Compliance 20 May - Annual Secretarial Compliance Report for FY ended March 31, 2026; no non-compliances found.